Clinical Research Study for Patients with Cutaneous T-cell Lymphoma
The Department of Dermatology at University Hospitals Case Medical Center in Cleveland, Ohio is conducting a clinical research study for patients with Cutaneous T-cell Lymphoma.
This research study is looking at an investigational drug, which is not FDA approved, called "Silicon phthalocyanine," or Pc 4 for short. This study is a Phase 1 Clinical Trial, meaning the FDA has not yet approved this medication and it is in the first stage of testing in people, focusing on safety and the ability of the drug to produce a beneficial change.
The purpose of this study is to see what happens to your CTCL and the sensitivity of your skin after applying the medication. Pc 4 is a topical medication that is applied to your skin lesions and activated by light. Eligible participants will be asked to come to University Hospitals Case Medical Center for 7 study visits over the course of one month.
You may qualify if you are 18 years or older and have Cutaneous T-cell Lymphoma/Mycosis Fungoides.
There is no cost to you or your insurance for participating in this research study. Participants will be compensated for their time and parking will be provided.
For more information, please contact the Skin Study Center at University Hospitals Case Medical Center at (216) 844 – SKIN (7546) or email Amanda Suggs, MD: Amanda.Suggs@UHhospitals.org.
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.